{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:15:58Z","timestamp":1761016558811},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.2515\/therapie:2006069","type":"journal-article","created":{"date-parts":[[2007,3,19]],"date-time":"2007-03-19T05:23:52Z","timestamp":1174281832000},"page":"379-387","source":"Crossref","is-referenced-by-count":19,"title":["Experimental Models of Thrombosis and Atherosclerosis"],"prefix":"10.1016","volume":"61","author":[{"given":"Tony J.","family":"Verbeuren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie:2006069_bb0010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.tcm.2004.04.002","article-title":"Cellular and Molecular Mechanisms of Atherosclerosis with Mouse Models","volume":"14","author":"Ohashi","year":"2004","journal-title":"Trends Cardiovasc Med"},{"key":"10.2515\/therapie:2006069_bb0015","doi-asserted-by":"crossref","first-page":"C7","DOI":"10.1016\/j.jacc.2005.09.068","article-title":"Pathogenesis of Atherosclerosis","volume":"47","author":"Falk","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.2515\/therapie:2006069_bb0020","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1161\/01.ATV.0000128849.12617.f4","article-title":"Atherosclerosis in the Apolipoprotein E-Deficient Mouse","volume":"24","author":"Meir","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.2515\/therapie:2006069_bb0025","first-page":"437","article-title":"Terutroban and endothelial TP receptors in atherogenesis","volume":"22","author":"Verbeuren","year":"2006","journal-title":"Med Sci"},{"key":"10.2515\/therapie:2006069_bb0030","first-page":"1324","article-title":"S 18204: A new powerful TXA2-receptor antagonist with a long duration of action","volume":"73","author":"Verbeuren","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.2515\/therapie:2006069_bb0035","series-title":"Recent advances in Prostaglandin","first-page":"173","article-title":"S 18886, a new thromboxane(TP)-receptor antagonist is the active isomer of S 18204 in all species, except in the guinea-pig","author":"Simonet","year":"1998"},{"key":"10.2515\/therapie:2006069_bb0040","first-page":"1724","article-title":"The thromboxane-receptor antagonist, S 18886 but not aspirin inhibits atherogenesis in apolipoprotein","volume":"20","author":"Cayatte","year":"2000","journal-title":"E deficient mice: Evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler. Thromb Vasc Biol"},{"key":"10.2515\/therapie:2006069_bb0045","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.CIR.101.10.1206","volume":"101","author":"Awtry","year":"2000","journal-title":"Aspirin. Circulation"},{"key":"10.2515\/therapie:2006069_bb0050","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0306-3623(88)90057-2","article-title":"Models of Thrombosis","volume":"19","author":"Hladovec","year":"1988","journal-title":"Gen Pharmac"},{"key":"10.2515\/therapie:2006069_bb0055","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1056-8719(00)00095-2","article-title":"Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents","volume":"43","author":"Leadley","year":"2000","journal-title":"J Pharmacol Toxicol Meth"},{"key":"10.2515\/therapie:2006069_bb0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF00878571","article-title":"Drugs for the prevention of coronary thrombosis: from an animal model to clinical trials","volume":"9","author":"Folts","year":"1995","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.2515\/therapie:2006069_bb201606301229207599","first-page":"9","article-title":"A survey of animal models to develop novel antithrombotic agents","author":"Jeske","year":"2003","journal-title":"New Therapeutic Agents in Thrombosis and Thrombolysis Marcel Dekker"},{"key":"10.2515\/therapie:2006069_bb0070","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1055\/s-0037-1613440","article-title":"In vivo pig models of venous thrombosis mimicking human disease","volume":"89","author":"Kang","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.2515\/therapie:2006069_bb0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bjp.0702030","article-title":"Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type 1 in rat models of venous and arterial thrombosis","volume":"125","author":"Berry","year":"1998","journal-title":"Brit J Pharmacol"},{"key":"10.2515\/therapie:2006069_bb0080","first-page":"252","article-title":"Experimental Carotid Thrombosis in the Guinea Pig","volume":"71","author":"Roux","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.2515\/therapie:2006069_bb0085","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.vascn.2005.06.006","article-title":"Adaptation of the Folts and electrolytic methods of arterial thrombosis for the study of anti-thrombotic molecules in small animals","volume":"53","author":"Sturgeon","year":"2006","journal-title":"J Pharmacol Toxicol Meth"},{"key":"10.2515\/therapie:2006069_bb0090","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.fjc.0000157439.49612.83","article-title":"Antithrombotic properties of the thromboxane A2\/prostaglandin H2 receptor antagonist S18886 on prevention of platelet-dependent cyclic flow reductions in dogs","volume":"45","author":"Maalej","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.2515\/therapie:2006069_bb0095","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0014-2999(00)00434-9","article-title":"Z-335, a new thromboxane A2 receptor antagonist, prevents arterial thrombosis induced by ferric chloride in rats","volume":"401","author":"Tanaka","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.2515\/therapie:2006069_bb0100","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1124\/jpet.103.063610","volume":"309","author":"Dogne","year":"2004","journal-title":"J Pharmacol Exper Ther"},{"key":"10.2515\/therapie:2006069_bb0105","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0049-3848(90)90106-M","article-title":"Rat model of arterial thrombosis induced by ferric chloride","volume":"60","author":"Kurz","year":"1990","journal-title":"Thromb Res"},{"key":"10.2515\/therapie:2006069_bb0110","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1538-7836.2006.01703.x","article-title":"Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor","volume":"4","author":"Wang","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.2515\/therapie:2006069_bb0115","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/10739680590925664","article-title":"Microvascular Thrombosis models in venules and arterioles in vivo","volume":"12","author":"Rumbaut","year":"2005","journal-title":"Microcirculation"},{"key":"10.2515\/therapie:2006069_bb0120","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1161\/01.ATV.0000163184.02484.69","article-title":"Importance of platelet phospholipase C?2 signaling in arterial thrombosis as a function of lesion severity","volume":"25","author":"Nonne","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.2515\/therapie:2006069_bb0125","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1055\/s-0037-1616758","article-title":"Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of a platelet-rich thrombus in rat mesenteric arterioles","volume":"86","author":"Rupin","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.2515\/therapie:2006069_bb0130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0021-9150(90)90178-L","article-title":"Animal models of atherosclerosis","volume":"85","author":"Armstrong","year":"1990","journal-title":"Atherosclerosis"},{"key":"10.2515\/therapie:2006069_bb0135","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1161\/01.ATV.20.11.2336","article-title":"Genetic modifiers of atherosclerosis in mice","volume":"20","author":"Knowles","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.2515\/therapie:2006069_bb0140","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/01.RES.58.4.552","article-title":"Effect of hypercholesterolemia on vascular reactivity in the rabbit: I. Endothelium-dependent and endothelium-independent contractions and relaxations in isolated arteries of control and hypercholesterolemic rabbits","volume":"58","author":"Verbeuren","year":"1986","journal-title":"Circulation Res"},{"key":"10.2515\/therapie:2006069_bb0145","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1161\/01.RES.59.5.496","article-title":"Effect of hypercholesterolemia on vascular reactivity in the rabbit. II. Influence of treatment with dipyridamole on endothelium-dependent and endothelium-independent responses in isolated aortas of control and hypercholesterolemic rabbits","volume":"59","author":"Verbeuren","year":"1986","journal-title":"Circ Res"},{"key":"10.2515\/therapie:2006069_bb0150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0021-9150(98)00254-8","article-title":"Distribution and prevalence of inducible nitric oxide synthase in atherosclerotic vessels of long-term cholesterol-fed rabbits","volume":"142","author":"Behr","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.2515\/therapie:2006069_bb0155","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0014-2999(90)94145-N","article-title":"Release and vascular activity of endothelium-derived relaxing factor in atherosclerotic rabbit aorta","volume":"191","author":"Verbeuren","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"10.2515\/therapie:2006069_bb0160","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1161\/01.RES.72.3.616","article-title":"Hypoxia causes an abnormal contractile response in the atherosclerotic rabbit aorta","volume":"72","author":"Simonet","year":"1993","journal-title":"Circ Res"},{"key":"10.2515\/therapie:2006069_bb0165","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/00005344-199305000-00023","article-title":"Evidence for induction of nonendothelial NO synthase in aortas of cholesterol-fed rabbits","volume":"21","author":"Verbeuren","year":"1993","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.2515\/therapie:2006069_bb0170","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0014-2999(99)00836-5","article-title":"Urinary nitrate excretion in cholesterol-fed rabbits: effect of a chronic treatment by N-iminoethyl-L-lysine, a selective inhibitor of inducible nitric oxide synthase","volume":"388","author":"Behr-Roussel","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.2515\/therapie:2006069_bb0175","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1003958312508","article-title":"Histochemical evidence for inducible nitric oxide synthase in advanced but non-ruptured human atherosclerotic carotid arteries","volume":"32","author":"Behr-Roussel","year":"2000","journal-title":"Histochem J"},{"key":"10.2515\/therapie:2006069_bb0180","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1161\/01.CIR.102.9.1033","article-title":"Effect of chronic treatment with the inducible nitric oxide synthase inhibitor N-iminoethyl-L-lysine or with L-arginine on progression of coronary and aortic atherosclerosis in hyperc-holesterolemic rabbits","volume":"102","author":"Behr-Roussel","year":"2000","journal-title":"Circulation"},{"key":"10.2515\/therapie:2006069_bb0185","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.atherosclerosis.2005.02.034","article-title":"S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits","volume":"183","author":"Worth","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.2515\/therapie:2006069_bb0190","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/eurheartj\/ehi175","article-title":"Atherosclerosis regression and TP receptor inhibition: effect of S 18886 on plaque size and composition a magnetic resonance imaging study","volume":"26","author":"Viles-Gonzalez","year":"2005","journal-title":"Eur Heart J"},{"key":"10.2515\/therapie:2006069_bb0195","first-page":"2867","article-title":"Involvement of thromboxane receptor in the proatherogenic effect of isoprostane F2a-III. Evidence from Apolipoprotein","volume":"112","author":"Tang","year":"2005","journal-title":"E and LDL receptor-deficient mice. Circulation"},{"key":"10.2515\/therapie:2006069_bb0200","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1161\/CIRCULATIONAHA.105.581892","article-title":"The thromboxane A2 receptor antagonist, S 18886, prevents enhanced atherogenesis caused by diabetes mellitus","volume":"112","author":"Zuccollo","year":"2005","journal-title":"Circulation"},{"key":"10.2515\/therapie:2006069_bb0205","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2337\/diabetes.55.01.06.db05-0831","article-title":"The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic Apo E-deficient mice","volume":"55","author":"Xu","year":"2006","journal-title":"Diabetes"},{"key":"10.2515\/therapie:2006069_bb0210","first-page":"468","article-title":"Spontaneous hypercholesterolemia and arterial lesions in mice lacking Apolipoprotein","volume":"258","author":"Zhang","year":"1992","journal-title":"E. Science"},{"key":"10.2515\/therapie:2006069_bb0215","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0092-8674(92)90362-G","article-title":"Severe hypercholesterolemia and atherosclerosis in Apolipoprotein E-deficient mice created by homologous recombination in ES cells","volume":"71","author":"Plump","year":"1992","journal-title":"Cell"},{"key":"10.2515\/therapie:2006069_bb0220","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/01.CIR.0000153386.95356.78","article-title":"Cyclooxygenases, thromboxane, and atherosclerosis","volume":"111","author":"Egan","year":"2005","journal-title":"Circulation"},{"key":"10.2515\/therapie:2006069_bb0225","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/01.CIR.91.3.776","article-title":"Triggering of plaque disruption and arterial thrombosis in an atherosclerotic rabbit model","volume":"91","author":"Abela","year":"1995","journal-title":"Circulation"},{"key":"10.2515\/therapie:2006069_bb0230","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1161\/01.CIR.0000158435.98035.8D","article-title":"Plaque rupture after short periods of fat feeding in the Apolipoprotein E-knockout mouse","volume":"111","author":"Johnson","year":"2005","journal-title":"Circulation"},{"key":"10.2515\/therapie:2006069_bb0235","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/01.ATV.0000219687.71607.f7","article-title":"A simple method of plaque rupture induction in Apolipoprotein E-deficient mice","volume":"26","author":"Sasaki","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.2515\/therapie:2006069_bb0240","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1161\/01.CIR.98.15.1541","article-title":"Non-invasive in vivo high-resolution magnetic resonance imaging of atherosclerotic lesions in genetically engineered mice","volume":"98","author":"Fayad","year":"1998","journal-title":"Circulation"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716304188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716304188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T03:01:50Z","timestamp":1554260510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716304188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S0040595716304188"],"URL":"https:\/\/doi.org\/10.2515\/therapie:2006069","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}